|
| |
Carragelose Shows Promising Antiviral Activity Against Common Cold in
Children - FFG to Give Significant Grant to Marinomed
FFG to Give Significant Grant to Marinomed
Vienna, Austria, 5 October, 2009 - Marinomed Biotechnologie GmbH, a
company focused on the development of innovative therapies in virology and
immunology, announced positive results in an interim analysis of an ongoing
clinical study investigating the effects of Carragelose® on the early treatment
of common cold symptoms in children. The results were presented on 2 October by
Dr. Philipp Eickhoff and the principal investigator Dr. Tamas Fazekas at the
Infectious Diseases session of the 47th Meeting of the Austrian society for
paediatrics (Österreichische Gesellschaft für Kinder und Jugendheilkunde) in
Graz, Austria. Carragelose® is the active ingredient of Coldamaris Prophylactic,
Marinomed’s first product, which is marketed in Austria under license with
Sigmapharm Arzneimittel GmbH & Co KG.
The ongoing study is a single centre, randomized, double-blind, parallel group,
placebo-controlled comparative study of 150 patients between one and 18 years
old (average age: five) at the St. Anna Children Hospital, Vienna (the leading
paediatric research institute in Austria). These interim results including 84
patients indicate that Carragelose® has an excellent safety profile and has
demonstrated an antiviral effect which resulted in a faster reduction of cold
symptoms compared to placebo.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “The excellent
safety profile of Coldamaris Prophylactic has once again been validated by this
St. Anna Children Study. However, we are especially delighted that the interim
results also indicate that Coldamaris Prophylactic appears to be an effective
antiviral treatment with a role to play in treating the viral cause of the
common cold.”
At the same time, Marinomed also announced that it has received, for the 3rd
year running, a significant grant from Österreichische
Forschungsförderungsgesellschaft (FFG) in subsidy and loan. A previous grant
from the FFG funded the St. Anna study described in this release. Marinomed
plans to use the funds for further investigation their lead compound Carragelose®
in other respiratory indications.
- ends -
About Marinomed Biotechnologie GmbH
Marinomed is a biopharmaceutical company discovering and developing innovative
naturally-derived immunological and antiviral treatments. The Company’s
discovery platform, Imuvirex®, is a broad combination of powerful in vitro and
in vivo screens that allow product candidates to be selected against viral and
immune targets. Marinomed has already used these platforms to discover and
develop Carragelose©, a unique broadly active antiviral compound for treating
respiratory diseases. Carragelose© is approved for marketing in the EU as an
anti-viral nasal spray and is also being investigated for use in a range of
other products. The second product candidate, MAM-06.301, is a “first in class”
compound in Phase II for allergy. Marinomed has an additional pipeline of
preclinical programmes for immune-based disorders and infectious diseases.
Located in Vienna, Austria, Marinomed was founded in March 2006 as a spin-off
from the University of Veterinary Medicine Vienna. Further information on
Marinomed can be found at www.marinomed.com
Contact:
Johanna Uhlmann
Business Development
Marinomed Biotechnologie GmbH
Tel: +43 (0)1 25077 4460
Johanna.uhlmann@marinomed.com
Dr. Douglas Pretsell
Senior Account Director
College Hill
Tel: +49 (0) 89 5700 1806
douglas.pretsell@collegehill.com
| |
|
